Tweets
🔬 Can baseline T cell phenotype predict PsA treatment response?
COLIPSO cohort (n=17): YES!
Higher Treg & activated CD4+ cells predict DAPSA & joint improvement
#POS0083 #EULAR2026 @RheumNow https://t.co/UIs6LXAWAY
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 9 minutes ago
🧬 Does spine vs knee enthesis differ immunologically?
Translational scRNAseq study: YES!
Spine produces more IL-23 but shows attenuated IL-17 response vs knee
#POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 9 minutes ago
🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA?
SPACE cohort (n=669):
HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%)
#OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour ago
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology
EULAR launches a Study Group on Geriatric Rheumatology — clinics increasingly serve older patients with multimorbidity, polypharmacy, frailty, cognitive and functional limits, yet research
Dr. John Cush @RheumNow ( View Tweet )
1 hour 19 minutes ago
🎗️ Do targeted therapies raise cancer risk in SpA?
French nationwide cohort (n=56,591): NO
In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological.
#OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 34 minutes ago
💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA?
Phase 3 RCT (n=304):
ASAS40 39.7% vs 24.8% placebo at week 12
with sustained benefit at week 24
#OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 34 minutes ago
Window of opportunity in stills disease is early. With IL1 / IL6 agents
#sJIA and #AOSD are the same disease. - may need a standard new crieteria
IL18 measuremnet should be encouraged.
@RheumNow #EULAR2026 plenary https://t.co/EQbs9mDYjS
Links:
Bella Mehta @bella_mehta ( View Tweet )
1 hour 35 minutes ago
Who should we screen for RA-ILD?
RA-ILD remains a serious extra-articular manifestation, contributing to morbidity and mortality.
At #EULAR2026, two abstracts shed light on clinical phenotyping and risk profiling.
Read my report for @RheumNow:
https://t.co/CTtYHINXxU
Mrinalini Dey @DrMiniDey ( View Tweet )
1 hour 35 minutes ago
Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be done with administrative support and the right hand off.
@RheumNow #EULAR2026 plenary talk https://t.co/N8qB7jrZfM
Links:
Bella Mehta @bella_mehta ( View Tweet )
1 hour 35 minutes ago
💊 After TNFi failure in axSpA, switch to IL-17Ai or cycle TNFi?
ROC-SpA (Phase 4 RCT, n=300):
NO difference: ASAS40 15.2% vs 14.5% at week 24
#OP0235 #EULAR2026 @RheumNow https://t.co/45gisWiuoM
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 35 minutes ago
🔬 Can filgotinib improve axSpA?
OLINGUITO (Phase 3 RCT, n=495):
YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16
#OP0234 #EULAR2026 @RheumNow https://t.co/0vj2KqSS1b
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 35 minutes ago
⚖️ Does BMI outrank treatment in early PsA outcomes?
YES - SPEED trial AI analysis:
BMI #1 predictor of PASDAS at 1yr in 192pts
#OP0187 #EULAR2026 @RheumNow https://t.co/9cZG7AWau2
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
1 hour 35 minutes ago
